Advances in anlotinib combined with cranial radiotherapy for brain metastases from advanced non-small cell lung cancer
Non-small cell lung cancer (NSCLC) has a persistently high incidence and mortality rate, and brain metastasis is one of the common complications with a poor prognosis. At present, cranial radiotherapy is a key treatment for controlling the progression of brain metastases, but its efficacy remains limited. Anlotinib is a multitarget tyrosine kinase inhibitor that can significantly prolong the survival of patients with advanced NSCLC. Clinical studies have found that anlotinib combined with cranial radiotherapy can delay the progression of brain metastases with good safety. This review mainly discusses the mechanisms and clinical efficacy of this combination strategy in NSCLC with brain metastases, aiming to provide a new and effective therapeutic option for these patients.
Authors
- 龙凤尧
- Yaqian Li
- Nuoyu Yan
- Lan Sun
Institutions
- Chongqing Medical University (CN)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2026-11-19
- DOI
- https://doi.org/10.3389/fneur.2026.2004058
- Primary Topic
- Brain Metastases and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00